

Client: Example Client ABC123  
123 Test Drive  
Salt Lake City, UT 84108  
UNITED STATES

Physician: Doctor, Example

**Patient: Patient, Example**

**DOB:** 8/8/1977  
**Gender:** Male  
**Patient Identifiers:** 01234567890ABCD, 012345  
**Visit Number (FIN):** 01234567890ABCD  
**Collection Date:** 00/00/0000 00:00

**Drug Profile, Targeted with Interpretation by Tandem Mass Spectrometry and Enzyme Immunoassay, Urine**

ARUP test code 2009288

Creatinine, Urine <20.0 mg/dL (Ref Interval: 20.0-400.0)

Creatinine <20 mg/dL is consistent with a dilute urine specimen. Recollection to obtain a more concentrated specimen, such as a first morning void, may be considered if unexpected negative urine drug screening results were obtained.

**Targeted Drug Profile Interpretation**

Inconsistent

DRUGS EXPECTED:  
XANAX (ALPRAZOLAM)

INCONSISTENT with medications provided:  
XANAX (ALPRAZOLAM): based on the absence of alprazolam and metabolite

Creatinine <20 mg/dL is consistent with a dilute urine specimen. Recollection to obtain a more concentrated specimen, such as a first morning void, may be considered if unexpected negative urine drug screening results were obtained.

INTERPRETIVE INFORMATION: Targeted drug profile Interp

Interpretation depends on accuracy and completeness of patient medication information submitted by client.

**Barbiturates Screen, U**

Negative

Presumptive negative by immunoassay. Testing by mass spectrometry is available on request.

INTERPRETIVE INFORMATION: Barbiturates Screen, U

Positive Cutoff: 200 ng/mL  
Methodology: Immunoassay

**Cocaine Screen, U**

Negative

H=High, L=Low, \*=Abnormal, C=Critical

Presumptive negative by immunoassay. Testing by mass spectrometry is available on request.

INTERPRETIVE INFORMATION: Cocaine Screen, U

Positive Cutoff: 150 ng/mL  
Methodology: Immunoassay

Carisoprodol Screen, U

Negative

Presumptive negative by immunoassay. Testing by mass spectrometry is available on request.

INTERPRETIVE INFORMATION: Carisoprodol Screen, U

Positive Cutoff: 100 ng/mL  
Methodology: Immunoassay

The carisoprodol immunoassay has cross-reactivity to carisoprodol and meprobamate.

Ethyl Glucuronide Screen, U

Negative

Presumptive negative by immunoassay. Testing by mass spectrometry is available on request.

INTERPRETIVE INFORMATION: Ethyl Glucuronide Screen, U

Positive Cutoff: 500 ng/mL  
Methodology: Immunoassay

THC (Cannabinoids) Screen, U

Negative

Presumptive negative by immunoassay. Testing by mass spectrometry is available on request.

INTERPRETIVE INFORMATION: THC (Cannabinoids) Screen, U

Positive Cutoff: 50 ng/mL  
Methodology: Immunoassay

Methadone Screen, U

Negative

Presumptive negative by immunoassay. Testing by mass spectrometry is available on request.

INTERPRETIVE INFORMATION: Methadone Screen, U

Positive Cutoff: 150 ng/mL  
Methodology: Immunoassay

Phencyclidine Screen, U

Negative

Presumptive negative by immunoassay. Testing by mass spectrometry is available on request.

**H=High, L=Low, \*=Abnormal, C=Critical**

INTERPRETIVE INFORMATION: Phencyclidine Screen, U  
Positive Cutoff: 25 ng/mL  
Methodology: Immunoassay

Tramadol Screen, U

Negative  
Presumptive negative by immunoassay. Testing by mass spectrometry is available on request.  
INTERPRETIVE INFORMATION: Tramadol Screen, U  
Positive Cutoff: 100 ng/mL  
Methodology: Immunoassay

6-acetylmorphine, U

Not Detected  
INTERPRETIVE INFORMATION: 6-acetylmorphine, U  
Positive Cutoff: 20 ng/mL  
Methodology: Mass Spectrometry

7-Aminoclonazepam, U

Not Detected  
INTERPRETIVE INFORMATION: 7-Aminoclonazepam, U  
Positive Cutoff: 40 ng/mL  
Methodology: Mass Spectrometry

Alpha-OH-Alprazolam, U

Not Detected  
INTERPRETIVE INFORMATION: Alpha-OH-Alprazolam, U  
Positive Cutoff: 20 ng/mL  
Methodology: Mass Spectrometry

Alpha-OH-Midazolam, U

Not Detected  
INTERPRETIVE INFORMATION: Alpha-OH-Midazolam, U  
Positive Cutoff: 20 ng/mL  
Methodology: Mass Spectrometry

Alprazolam, U

Not Detected  
INTERPRETIVE INFORMATION: Alprazolam, U  
Positive Cutoff: 40 ng/mL  
Methodology: Mass Spectrometry

Amphetamine, U

Not Detected  
INTERPRETIVE INFORMATION: Amphetamine, U  
Positive Cutoff: 50 ng/mL  
Methodology: Mass Spectrometry

Buprenorphine, U

Not Detected  
INTERPRETIVE INFORMATION: Buprenorphine, U  
Positive Cutoff: 5 ng/mL  
Methodology: Mass Spectrometry

**H=High, L=Low, \*=Abnormal, C=Critical**

Clonazepam, U	Not Detected INTERPRETIVE INFORMATION: Clonazepam, U Positive Cutoff: 20 ng/mL Methodology: Mass Spectrometry
Codeine, U	Not Detected INTERPRETIVE INFORMATION: Codeine, U Positive Cutoff: 40 ng/mL Methodology: Mass Spectrometry
Diazepam, U	Not Detected INTERPRETIVE INFORMATION: Diazepam, U Positive Cutoff: 50 ng/mL Methodology: Mass Spectrometry
Fentanyl, U	Not Detected INTERPRETIVE INFORMATION: Fentanyl, U Positive Cutoff: 2 ng/mL Methodology: Mass Spectrometry
Gabapentin, U	Not Detected INTERPRETIVE INFORMATION: Gabapentin, U Positive Cutoff: 3,000 ng/mL Methodology: Mass Spectrometry
Hydrocodone, U	Not Detected INTERPRETIVE INFORMATION: Hydrocodone, U Positive Cutoff: 40 ng/mL Methodology: Mass Spectrometry
Hydromorphone, U	Not Detected INTERPRETIVE INFORMATION: Hydromorphone, U Positive Cutoff: 20 ng/mL Methodology: Mass Spectrometry
Lorazepam, U	Not Detected INTERPRETIVE INFORMATION: Lorazepam, U Positive Cutoff: 60 ng/mL Methodology: Mass Spectrometry
MDA, U	Not Detected INTERPRETIVE INFORMATION: MDA, U Positive Cutoff: 200 ng/mL Methodology: Mass Spectrometry
MDEA, U	Not Detected

**H=High, L=Low, \*=Abnormal, C=Critical**

*Unless otherwise indicated, testing performed at:*

INTERPRETIVE INFORMATION:MDEA, U  
Positive Cutoff: 200 ng/mL  
Methodology: Mass Spectrometry

MDMA, U

Not Detected  
INTERPRETIVE INFORMATION:MDMA, U  
Positive Cutoff: 200 ng/mL  
Methodology: Mass Spectrometry

Meperidine metabolite, U

Not Detected  
INTERPRETIVE INFORMATION:Meperidine metabolite, U  
Positive Cutoff: 50 ng/mL  
Methodology: Mass Spectrometry

Methamphetamine, U

Not Detected  
INTERPRETIVE INFORMATION:Methamphetamine, U  
Positive Cutoff: 200 ng/mL  
Methodology: Mass Spectrometry

Methylphenidate, U

Not Detected  
INTERPRETIVE INFORMATION:Methylphenidate, U  
Positive Cutoff: 100 ng/mL  
Methodology: Mass Spectrometry

Midazolam, U

Not Detected  
INTERPRETIVE INFORMATION:Midazolam, U  
Positive Cutoff: 20 ng/mL  
Methodology: Mass Spectrometry

Morphine, U

Not Detected  
INTERPRETIVE INFORMATION:Morphine, U  
Positive Cutoff: 20 ng/mL  
Methodology: Mass Spectrometry

Naloxone, U

Not Detected  
INTERPRETIVE INFORMATION:Naloxone, U  
Positive Cutoff: 100 ng/mL  
Methodology: Mass Spectrometry

Norbuprenorphine, U

Not Detected  
INTERPRETIVE INFORMATION:Norbuprenorphine, U  
Positive Cutoff: 20 ng/mL  
Methodology: Mass Spectrometry

Nordiazepam, U

Not Detected

**H=High, L=Low, \*=Abnormal, C=Critical**

INTERPRETIVE INFORMATION: Nordiazepam, U  
Positive Cutoff: 50 ng/mL  
Methodology: Mass Spectrometry

Norfentanyl, U

Not Detected  
INTERPRETIVE INFORMATION: Norfentanyl, U  
Positive Cutoff: 2 ng/mL  
Methodology: Mass Spectrometry

Norhydrocodone, U

Not Detected  
INTERPRETIVE INFORMATION: Norhydrocodone, U  
Positive Cutoff: 100 ng/mL  
Methodology: Mass Spectrometry

Noroxycodone, U

Not Detected  
INTERPRETIVE INFORMATION: Noroxycodone, U  
Positive Cutoff: 100 ng/mL  
Methodology: Mass Spectrometry

Noroxymorphone, U

Not Detected  
INTERPRETIVE INFORMATION: Noroxymorphone, U  
Positive Cutoff: 100 ng/mL  
Methodology: Mass Spectrometry

Oxazepam, U

Not Detected  
INTERPRETIVE INFORMATION: Oxazepam, U  
Positive Cutoff: 50 ng/mL  
Methodology: Mass Spectrometry

Oxycodone, U

Not Detected  
INTERPRETIVE INFORMATION: Oxycodone, U  
Positive Cutoff: 40 ng/mL  
Methodology: Mass Spectrometry

Oxymorphone, U

Not Detected  
INTERPRETIVE INFORMATION: Oxymorphone, U  
Positive Cutoff: 40 ng/mL  
Methodology: Mass Spectrometry

Phentermine, U

Not Detected  
INTERPRETIVE INFORMATION: Phentermine, U  
Positive Cutoff: 100 ng/mL  
Methodology: Mass Spectrometry

Pregabalin, U

Not Detected

**H=High, L=Low, \*=Abnormal, C=Critical**

INTERPRETIVE INFORMATION: Pregabalin, U  
Positive Cutoff: 3,000 ng/mL  
Methodology: Mass Spectrometry

Tapentadol, U

Not Detected  
INTERPRETIVE INFORMATION: Tapentadol, U  
Positive Cutoff: 100 ng/mL  
Methodology: Mass Spectrometry

Tapentadol-o-Sulf, U

Not Detected  
INTERPRETIVE INFORMATION: Tapentadol-o-Sulf, U  
Positive Cutoff: 200 ng/mL  
Methodology: Mass Spectrometry

Temazepam, U

Not Detected  
INTERPRETIVE INFORMATION: Temazepam, U  
Positive Cutoff: 50 ng/mL  
Methodology: Mass Spectrometry

Zolpidem, U

Not Detected  
INTERPRETIVE INFORMATION: Zolpidem, U  
Positive Cutoff: 20 ng/mL  
Methodology: Mass Spectrometry

Zolpidem Metabolite, U

Not Detected  
INTERPRETIVE INFORMATION: Zolpidem Metabolite, U  
Positive Cutoff: 100 ng/mL  
Methodology: Mass Spectrometry

Targeted Drug Profile Comment

See Below

**H=High, L=Low, \*=Abnormal, C=Critical**

Methodology: Qualitative Enzyme Immunoassay and Qualitative Liquid Chromatography-Tandem Mass Spectrometry, Quantitative Spectrophotometry

The absence of expected drug(s) and/or drug metabolite(s) may indicate non-compliance, inappropriate timing of specimen collection relative to drug administration, poor drug absorption, diluted/adulterated urine, or limitations of testing. The concentration must be greater than or equal to the cutoff to be reported as present. If specific drug concentrations are required, contact the laboratory within two weeks of specimen collection to request quantification by a second analytical technique. Interpretive questions should be directed to the laboratory.

Results based on immunoassay detection that do not match clinical expectations should be interpreted with caution. Confirmatory testing by mass spectrometry for immunoassay-based results is available, if ordered within two weeks of specimen collection. Additional charges apply.

For medical purposes only; not valid for forensic use.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

EER Targeted Drug Profile, U

See Note

Authorized individuals can access the ARUP Enhanced Report using the following link:

[Redacted Link]

VERIFIED/REPORTED DATES

Procedure	Accession	Collected	Received	Verified/Reported
Creatinine, Urine	23-331-138346	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Targeted Drug Profile Interpretation	23-331-138346	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Barbiturates Screen, U	23-331-138346	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Cocaine Screen, U	23-331-138346	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Carisoprodol Screen, U	23-331-138346	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Ethyl Glucuronide Screen, U	23-331-138346	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
THC (Cannabinoids) Screen, U	23-331-138346	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Methadone Screen, U	23-331-138346	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Phencyclidine Screen, U	23-331-138346	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Tramadol Screen, U	23-331-138346	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
6-acetylmorphine, U	23-331-138346	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
7-Aminoclonazepam, U	23-331-138346	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00

H=High, L=Low, \*=Abnormal, C=Critical

Unless otherwise indicated, testing performed at:



Alpha-OH-Alprazolam, U	23-331-138346	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Alpha-OH-Midazolam, U	23-331-138346	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Alprazolam, U	23-331-138346	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Amphetamine, U	23-331-138346	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Buprenorphine, U	23-331-138346	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Clonazepam, U	23-331-138346	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Codeine, U	23-331-138346	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Diazepam, U	23-331-138346	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Fentanyl, U	23-331-138346	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Gabapentin, U	23-331-138346	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Hydrocodone, U	23-331-138346	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Hydromorphone, U	23-331-138346	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Lorazepam, U	23-331-138346	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
MDA, U	23-331-138346	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
MDEA, U	23-331-138346	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
MDMA, U	23-331-138346	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Meperidine metabolite, U	23-331-138346	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Methamphetamine, U	23-331-138346	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Methylphenidate, U	23-331-138346	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Midazolam, U	23-331-138346	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Morphine, U	23-331-138346	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Naloxone, U	23-331-138346	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Norbuprenorphine, U	23-331-138346	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Nordiazepam, U	23-331-138346	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Norfentanyl, U	23-331-138346	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Norhydrocodone, U	23-331-138346	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Noroxycodone, U	23-331-138346	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Noroxymorphone, U	23-331-138346	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Oxazepam, U	23-331-138346	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Oxycodone, U	23-331-138346	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Oxymorphone, U	23-331-138346	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Phentermine, U	23-331-138346	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Pregabalin, U	23-331-138346	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Tapentadol, U	23-331-138346	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Tapentadol-o-Sulf, U	23-331-138346	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Temazepam, U	23-331-138346	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Zolpidem, U	23-331-138346	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Zolpidem Metabolite, U	23-331-138346	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Targeted Drug Profile Comment	23-331-138346	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
EER Targeted Drug Profile, U	23-331-138346	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00

**H=High, L=Low, \*=Abnormal, C=Critical**

Unless otherwise indicated, testing performed at:

ARUP LABORATORIES | 800-522-2787 | aruplab.com  
500 Chipeta Way, Salt Lake City, UT 84108-1221  
Jonathan R. Genzen, MD, PhD, Laboratory Director

Patient: Patient, Example  
ARUP Accession: 23-331-138346  
Patient Identifiers: 01234567890ABCD, 012345  
Visit Number (FIN): 01234567890ABCD  
Page 9 of 10 | Printed: 1/18/2024 2:40:41 PM  
4848

END OF CHART

---

**H=High, L=Low, \*=Abnormal, C=Critical**

---

*Unless otherwise indicated, testing performed at:*

ARUP LABORATORIES | 800-522-2787 | aruplab.com  
500 Chipeta Way, Salt Lake City, UT 84108-1221  
Jonathan R. Genzen, MD, PhD, Laboratory Director

Patient: Patient, Example  
ARUP Accession: 23-331-138346  
Patient Identifiers: 01234567890ABCD, 012345  
Visit Number (FIN): 01234567890ABCD  
Page 10 of 10 | Printed: 1/18/2024 2:40:41 PM  
4848